Ligand id: 2421

Name: amiloride

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: amiloride

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 4
Rotatable bonds 2
Topological polar surface area 159.29
Molecular weight 229.05
XLogP -1.18
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

1. Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M et al.. (2013)
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Brain, 136 (Pt 1): 106-15. [PMID:23365093]
2. Inoue R, Okada T, Onoue H, Hara Y, Shimizu S, Naitoh S, Ito Y, Mori Y. (2001)
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
Circ. Res., 88 (3): 325-32. [PMID:11179201]
3. Killestein J, Kalkers NF, Polman CH. (2005)
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
J. Neurol. Sci., 233 (1-2): 113-5. [PMID:15949499]
4. Masereel B, Pochet L, Laeckmann D. (2003)
An overview of inhibitors of Na(+)/H(+) exchanger.
Eur J Med Chem, 38 (6): 547-54. [PMID:12832126]
5. Mostert J, Heersema T, Mahajan M, Van Der Grond J, Van Buchem MA, De Keyser J. (2013)
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
ISRN Neurol, 2013: 370943. [PMID:23984093]
6. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J. (2008)
Therapeutic potential of fluoxetine in neurological disorders.
CNS Neurosci Ther, 14 (2): 153-64. [PMID:18482027]
7. Nagata K, Duggan A, Kumar G, Garcia-Anoveros J. (2005)
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing.
J. Neurosci., 25 (16): 4052-61. [PMID:15843607]